Three times spontaneous remission of severe aplastic anemia following granulocyte transfusion from related donors: a case report and literature review / 中国医学科学杂志(英文版)

Aplastic anemia (AA) is a bone marrow failure disease caused by abnormal activation of T lymphocytes, resulting in the apoptosis of hematopoietic cells and bone marrow failure. Currently, hematopoietic stem cell transplantation (HSCT), immunosuppressive - therapy (IST), and supportive care (e.g. transfusion adjuvant therapy, hematopoietic growth factors, and prevention of infection) are the main treatments of AA. Granulocyte transfusion has recently been accepted as an useful adjuvant therapy of HSCT and intensive IST. This article reported a severe AA patient who failed to respond to IST, but achieved spontaneous remission three times after granulocyte transfusions from related donors. Such cases have rarely been reported. Existence of human leukocyte antigen (HLA) cross between the patient and his relatives may influence the T cell-mediated immunity, which might explain this patient's recovery.

Clinical observation of decitabine treatment for patients with acute myeloid leukemia / 肿瘤

Objective: To evaluate the clinical therapeutic effect and safety of decitabine in the treatment for adult acute myeloid leukemia (AML). Methods: Clinical information from 15 patients (> 18 years) with adult AML were collected between August 2009 and October 2010. The therapeutic effect and side reactions of decitabine were evaluated. Results: Of the 15 patients, 3 patients achieved complete remission (CR), five patients achieved partial remission (PR). The overall response rate was 53.3%. Of the 12 patients whose cytogenetic evaluation was accessible, one patient (8.3%) achieved complete cytogenetic remission. The median overall survival (OS) was 123 d (27-509 d), the median relapse-free survival (RFS) was 70 d (19-306 d), and the median duration of response was 33 d (11-176 d). The incidence rate of grade IV hematologic toxicity was 93.3%, and the incidence rate of grade III-IV infection was 33.3%. No severe bleeding, nausea and vomiting and liver injury (grade III-IV) were observed. Early death occurred in one patient. Conclusion: Decitabine can effectively treat adult AML with more severe hematologic toxicity, and it is necessary to give active supportive treatment. Copyright© 2011 by TUMOR.